Yaojun Wang1, Ying Cen, Zhengyong Li. 1. Department of Plastic and Burns Surgery, West China Hospital, Sichuan University, Chengdu Sichuan, P. R. China.
Abstract
OBJECTIVE: To observe the effects of operation with large-dose of Roferon-A for cutaneous malignant melanoma. METHODS: From January 1998 to December 2005, thirty-three patients with cutaneous malignant melanoma were treated. There were 20 males and 13 females, aging 17-79 years. The disease course was 2 months to 7 years. In 33 patients, nine patients identified as clinical-stage I received singly enlarged-resection to the primary lesion and performed split-thickness skin graft dermoplasty or adjacent skin flap repair; twenty-three patients identified as clinical-stage II received enlarged-resection to the primary lesion and performed proximal lymphaden scavenge as well as received split-thickness skin graft dermoplasty; and one patient identified as clinical-stage III received palliative resection to the primary lesion. All patients received large dose of, Roferon-A after operation. RESULTS: There are no recidivation in the 9 patients of clinical-stage I. There are 1 recidivation and 1 quit in all the 23 patients of clinical-stage II. One patient of clinical-stage III died after 18 months of operation. CONCLUSION: The operation combined with large-dose of Roferon-A after operation was a more effective way to treat cutaneous malignant melanoma.
OBJECTIVE: To observe the effects of operation with large-dose of Roferon-A for cutaneous malignant melanoma. METHODS: From January 1998 to December 2005, thirty-three patients with cutaneous malignant melanoma were treated. There were 20 males and 13 females, aging 17-79 years. The disease course was 2 months to 7 years. In 33 patients, nine patients identified as clinical-stage I received singly enlarged-resection to the primary lesion and performed split-thickness skin graft dermoplasty or adjacent skin flap repair; twenty-three patients identified as clinical-stage II received enlarged-resection to the primary lesion and performed proximal lymphaden scavenge as well as received split-thickness skin graft dermoplasty; and one patient identified as clinical-stage III received palliative resection to the primary lesion. All patients received large dose of, Roferon-A after operation. RESULTS: There are no recidivation in the 9 patients of clinical-stage I. There are 1 recidivation and 1 quit in all the 23 patients of clinical-stage II. One patient of clinical-stage III died after 18 months of operation. CONCLUSION: The operation combined with large-dose of Roferon-A after operation was a more effective way to treat cutaneous malignant melanoma.